drugset
drugset / Trial / NCT05339100

Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab

NCT05339100 ↗

Phase 1 Completed 180 enrolled AstraZeneca Parexel · collab
RandomizedParallel-groupOpen-labelOther

Summary

This study will be conducted to compare the pharmacokinetic (PK) exposure after a single SC dose of anifrolumab administered using an AI with the PK exposure after a single subcutaneous (SC) dose of anifrolumab administered using APFS in healthy male and female volunteers.

Timeline

Start
2022-03-22
Primary completion
2023-04-13
Completion
2023-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Anifrolumab Monoclonal antibody — Subcutaneous

Indications

No indication recorded.